AC PENRHYN 100 INSECT GROWTH REGULATOR Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ac penrhyn 100 insect growth regulator

axichem pty ltd - pyriproxyfen; liquid hydrocarbon - emulsifiable concentrate - pyriproxyfen pyridine active 100.0 g/l; liquid hydrocarbon solvent other 450.0 g/l - insecticide

GNOME-BLUES LTD TEA TREE OIL melaleuca oil        application bottle Australia - English - Department of Health (Therapeutic Goods Administration)

gnome-blues ltd tea tree oil melaleuca oil application bottle

main camp marketing pty ltd - melaleuca oil, quantity: 1000 mg/ml - application - excipient ingredients: - natural antiseptic, antibacterial and antifungal remedy.

Abbey FLY AND LICE JETTING FLUID Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey fly and lice jetting fluid

abbey laboratories pty ltd - ivermectin - topical solution/suspension - ivermectin anthelmintic active 16.0 g/l - parasiticides

Save-A-Lot Food Stores, Ltd. Omeprazole Delayed Release Tablets 20 mg Drug Facts United States - English - NLM (National Library of Medicine)

save-a-lot food stores, ltd. omeprazole delayed release tablets 20 mg drug facts

save-a-lot food stores ltd - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - acid reducer

MOXXI POUR-ON FOR CATTLE AND RED DEER Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

moxxi pour-on for cattle and red deer

abbey laboratories pty ltd - moxidectin; liquid hydrocarbon - topical solution/suspension - moxidectin anthelmintic active 5.0 g/l; liquid hydrocarbon solvent other 150.0 g/l - parasiticides

Nia Pharmaceuticals Pty Ltd - Lubricant, eye Australia - English - Department of Health (Therapeutic Goods Administration)

nia pharmaceuticals pty ltd - lubricant, eye

nia pharmaceuticals pty ltd - 44237 - lubricant, eye - ophthalmic solution moisturizing, lubricating and refreshing particularly suitable for dry eyes and improving the comfort of contact lenses worn. indications: lubricating, moisturizing and refreshing; ideal in case of non-traumatic/non-pathological alterations of the tear film; environmental ocular stress (wind, dust, air conditioning, dry and polluted air, etc.); ocular stress (extended computer use, unfavourable lighting conditions, night driving etc.); indicated in case of extended use of contact lenses; indicated to improve the comfort of the worn contact lenses and reduce fogging; indicated for the prevention of the dirt deposits and the dehydration of the lens; indicated to be used also with contact lenses worn; eliminate the device according to the current legislation

OPSUMIT Israel - English - Ministry of Health

opsumit

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

ATRIPLA Israel - English - Ministry of Health

atripla

gilead sciences israel ltd - efavirenz; emtricitabine; tenofovir disoproxil as - film coated tablets - tenofovir disoproxil as 245 mg; emtricitabine 200 mg; efavirenz 600 mg - tenofovir disoproxil - atripla is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.

ICLUSIG 15 MG Israel - English - Ministry of Health

iclusig 15 mg

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.